Anti-CTLA4 and anti-PD-L1/PD-1 therapeutic antibodies have revolutionized the field of clinical oncology, enabling physicians to advance therapy beyond traditional chemotherapy and RT, thereby increasing curability and prolonging the survival of patients with previously incurable cancers. Here, CTLA4 is linked to cancer.